SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-23-215969
Filing Date
2023-08-18
Accepted
2023-08-18 16:16:55
Documents
1
Group Members
ABINGWORTH BIOVENTURES VI LPABINGWORTH LLPCARLYLE GENESIS UK LLCCARLYLE HOLDINGS I GP INC.CARLYLE HOLDINGS I GP SUB L.L.C.CARLYLE HOLDINGS I L.P.CARLYLE INVESTMENT MANAGEMENT L.L.C.CG SUBSIDIARY HOLDINGS L.L.C.TC GROUP, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d542030dsc13da.htm SC 13D/A 185486
  Complete submission text file 0001193125-23-215969.txt   187687
Mailing Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Business Address C/O THE CARLYLE GROUP 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004 202 729 5626
Carlyle Group Inc. (Filed by) CIK: 0001527166 (see all company filings)

IRS No.: 452832612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 6282 Investment Advice

Mailing Address 142 NORTH CEDROS AVENUE, SUITE B SOLANA BEACH CA 92075
Business Address 142 NORTH CEDROS AVENUE, SUITE B SOLANA BEACH CA 92075 (858) 925-8215
eFFECTOR Therapeutics, Inc. (Subject) CIK: 0001828522 (see all company filings)

IRS No.: 853306396 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91982 | Film No.: 231186071
SIC: 2834 Pharmaceutical Preparations